Labo Crescina Transdermic Rapid-Intensive 2100 Hair Loss + Regrowth Treatment Man

264.00334.00
224.40283.90

Labo Crescina Transdermic Rapid-Intensive 2100 Double Treatment Man 10+10 20+20 Vials (1-2 treatmeant months)
ANTI HAIR LOSS – REGROWTH

discover the formulations and patents here

  • Double anti-hair loss treatment + intensive rapid regrowth for thinned scalp.
  • Contrasts hair loss and promotes regrowth. Components similar to the molecules naturally present in the hair system stimulate the regeneration of the hair. Acts on Follicular Island.
  • All treatments are available in specific formulas for men and women.
    Increasing dosages from 200 to 2100 according to the degree of thinning
  • The Crescina Transdermic Re-Growth Rapid-Intensive vials (amber vials) contain the complex of 12 Plate-Like molecules that physiologically and synergistically promotes hair growth, associated with the Bulge-Stem complex capable of protecting and maintaining the environment of the bulge, inside the hair follicle, and the new Scalp Microbiome Complex, to rebalance the functionality of the beneficial microorganisms naturally present on the scalp.
  • Additional active ingredients included: Re-Growth complex, HFSC complex, 3 + 2 enhancer.
  • Crescina Transdermic Anti-Fall Forte vials (colorless vials) contain the basic active ingredients and the active ingredients Hydrolyzed Yeast Protein and Acetyl Tetrapeptide-3, useful for strengthening the hair at the root, three plate-like molecules and three enhancers to assist its penetration in the hair system and scalp. The formula is enriched with the HSSC complex.
Clear
 

Description

Hair loss

Hair loss in normal conditions is to be considered a natural physiological process of hair replacement. Hair growth, loss and regrowth are part of the hair life cycle, a sequence that is repeated continuously throughout a person’s life.

As long as hair loss is within the confines of this regrowth cycle it needn’t worry. However, when the phenomenon is triggered by exogenous, genetic or hormonal factors, it is possible that the falling structures are not adequately replaced by equally healthy hair.

Depending on the characteristics of the person and other factors such as problems with the scalp or the hair bulb, hair loss can manifest itself in many different forms. Baldness, or androgenetic alopecia, is the most common hair problem. More than 70% of men and 40% of women are affected in their lifetime.

Crescina

The new Crescina Transdermic Rapid-Intensive acts on the thinned scalp and thanks to its direct action within the hair follicle, where the cells responsible for initiating new hair life cycles are stored, physiologically and synergistically promotes growth. of the hair. Furthermore, thanks to its components similar to the molecules naturally present in the hair system, it stimulates the regeneration of the hair in a targeted way.

The Complete Rapid-Intensive Crescina Transdermic Re-Growth and Anti-Fall Treatment is a topical cosmetic treatment that combines the two types of vials in a single package.

To ensure that the functional molecules of Crescina penetrate not only from the follicular ostia but also through the scalp to reach the hair system, Labo researchers have developed a “Transdermal” technology based on the low molecular weight of active substances and on the presence of enhancers, for their penetration into the skin layers of the scalp.

 

Follicular Island

Unlike single follicles that are valid for only one hair, FOLLICULAR ISLANDS, depending on the distribution and number, can count two or more hairs. With the thinning process, it is therefore essential to reserve a specific treatment for the follicular islands that is appropriate to the complexity of this extremely important system, in proportion to the total number of stems on the scalp.

 

Additional information

Formato

10+10, 20+20

Reviews

There are no reviews yet.

Be the first to review “Labo Crescina Transdermic Rapid-Intensive 2100 Hair Loss + Regrowth Treatment Man”

Your email address will not be published. Required fields are marked *